Vol 8, Issue 325
A nanoparticle formulation of an Aurora B inhibitor increases antitumor efficacy and reduces toxicity, which may be a precedent for the use of this technology with other small molecules (Ashton et al., this issue).
A nanoparticle formulation of an Aurora B kinase inhibitor uses ion pairing to achieve controlled release and efficacious, nontoxic target inhibition in tumors.
Lack of the skin barrier protein filaggrin worsens atopic dermatitis by allergenic activation of CD1a-reactive T cells.
Interfering with the stress protein FKBP51 can block chronic pain in mice and rats, suggesting its potential as a therapeutic target.
- Erratum for the Research Article: “Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans” by G. Reyes-Soffer, B. Moon, A. Hernandez-Ono, M. Dionizovick-Dimanovski, J. Jimenez, J. Obunike, T. Thomas, C. Ngai, N. Fontanez, D. S. Donovan, W. Karmally, S. Holleran, R. Ramakrishnan, R. S. Mittleman, H. N. Ginsberg